

Glu-C – an orthogonal and alternative enzyme for protein quantitation by LC-MS/MS



Szabolcs Szarka, Senior Scientist
Drug Development Services, LGC

Science
for a safer world



LC-MS/MS for protein quantification



- Pros
 - Highly selective (metabolites, degradation products)
 - Improved accuracy
 - Multiplexing (simultaneous analysis of multiple proteins)
- Technique
 - Targeted “bottom-up” → sensitivity and specificity
 - Proteins are digested → analysis at peptide level (signature peptide approach)
 - Trypsin – most commonly used

Glu-C

- Glutamyl endopeptidase
- Bacterial Ser-protease (*Staphylococcus aureus*)
- Cleaves after Glu and Asp
- Favors Glu at pH8 in ammonium buffer
- Product are peptides with acidic C-terminal → orthogonal to trypsin
- Price comparable to trypsin
- Patented generic tryptic signature peptides (2014 March: US, 2016 February: EU)

Model analyte – bispecific IgG1

- Bispecific mAbs
 - Different Fab regions → different specificity → complex activity
 - Highly specific and complex functions and mechanism of action
 - Less adverse side effects
 - Complex structure
 - Increasing interest on bispecific mAbs



Method Development Workflow

- *In silico* digestion
 - ↓ Selection of the appropriate digestion enzyme
 - ↓ Initial BLAST screen
- Peptide mapping (HRAM-MS)
- Sample preparation
- Sample cleanup and LC-MS/MS optimization

**Generic LC-MS/MS
quantitation method**


Goal

- To set up a generic mAb quantitation method in pre-clinical matrices using Glu-C digestion
- Requirements:
 - Simple sample preparation
 - LLOQ of 1 $\mu\text{g}/\text{mL}$ using 10 μL sample

Instrumentation


- Peptide mapping
 - Waters Synapt G2 Q-TOF
 - MS^E acquisition

- Quantitation
 - Waters Xevo TQ-S
 - Waters Acquity UPLC
 - LC separation: Acquity HSS T3 column (100 x 2.1 mm, 1.7 μm particles)




Peptide mapping

- Generic signature peptides
 - Peptides from the heavy chain constant domain
 - Few are unique to human
 - Those that are – are not highly sensitive



Peptide mapping

- Generic signature peptides
 - What about monkey? → Light chains come in handy
 - Two light chain classes: λ and κ → different constant region




Digestion optimization

- Sample preparation
 - pellet digestion*
- Digestion conditions

LLGG normalised peak area		
Enzyme conc. (µg/mL)	Digestion time	
	2 h	overnight
0.3	0.50	31
3.0	17	93
30	34	100





- Denaturing reagent




- Optimal conditions
 - overnight digestion with 3.0 µg/mL Glu-C
 - 6 M guanidine

IgG1 heavy chain LC-MS/MS

Generic signature peptide: LLGGPSVFLFPPKPKDTLMISRTPE



IgG1 heavy chain LC-MS/MS precision and accuracy



IgG1 heavy chain peptide in rat



QC level	Conc. (µg/mL)	Mean (µg/mL)	%CV	%RE
LLOQ	1	1.0	4.2	-2.1
Low	3	2.9	3.4	-5.1
Medium	40	38.8	7.0	-3.0
High	400	364.6	6.7	-8.9

IgG1 heavy chain peptide in mouse


QC level	Conc. (µg/mL)	Mean (µg/mL)	%CV	%RE
LLOQ	1	0.9	3.2	-4.9
Low	3	2.7	6.7	-8.2
Medium	40	40.5	3.3	1.2
High	400	398.0	3.2	-0.5

IgG1 light chain LC-MS/MS

Generic light chain signature peptides in monkey serum



IgG1 light chain LC-MS/MS precision and accuracy



IgG1 light chain κ peptide in monkey

QC level	Conc. ($\mu\text{g/mL}$)	Mean ($\mu\text{g/mL}$)	%CV	%RE
LLOQ	1	0.93	14.6	-6.7
Low	3	3.18	17.1	6.1
Medium	40	40.43	4.5	1.1
High	400	408.75	3.6	2.2

IgG1 light chain λ peptide in monkey

QC level	Conc. ($\mu\text{g/mL}$)	Mean ($\mu\text{g/mL}$)	%CV	%RE
LLOQ	1	1.00	10.9	0.0
Low	3	2.78	4.8	-7.2
Medium	40	37.63	1.7	-5.9
High	400	385.93	3.9	-3.5

Conclusions

- Glu-C digestion provides an efficient alternative means for quantification of biopharmaceuticals in biological samples
 - Two assays have been developed
 1. Heavy chain generic peptide → rodents
 2. Two light chain generic peptides (κ and λ) → monkey samples
 - Satisfactory assay performance, even with no IS
 - Sensitivity (LLOQ) is comparable to a trypsin digestion approach
 - Work around current patent
- in the pipeline
 - Cross validation against ligand binding assay data



Acknowledgements

Colleagues at LGC

- Kjetil Hansen*
- Mark Hows
- Richard Kay@

Novimmune

- Emilie Escoffier
- Robert Nelson

*present affiliation: King's College London

@present affiliation: Cambridge University

Thank you



Szabolcs Szarka, Senior Scientist
Drug Development Services, LGC

Science
for a safer world

